Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KAN.ST
- Price
- 1.20
- Stock movement up
- +0.03 (2.57%)
- Company name
- Kancera AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 145.18M
- Ent value
- 92.84M
- Price/Sales
- 327.72
- Price/Book
- 2.02
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.70%
- 1 year return
- -21.90%
- 3 year return
- -39.90%
- 5 year return
- -20.65%
- 10 year return
- -29.08%
Last updated: 2025-04-12
DIVIDENDS
KAN.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 327.72 |
| Price to Book | 2.02 |
| EV to Sales | 209.57 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 121.19M |
| EPS (TTM) | -0.44 |
| FCF per share (TTM) | -0.49 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 443.00K |
| Gross profit (TTM) | 443.00K |
| Operating income (TTM) | -55.68M |
| Net income (TTM) | -53.40M |
| EPS (TTM) | -0.44 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -12568.85% |
| Profit margin (TTM) | -12053.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 57.93M |
| Net receivables | 0.00 |
| Total current assets | 59.52M |
| Goodwill | 0.00 |
| Intangible assets | 18.00M |
| Property, plant and equipment | 0.00 |
| Total assets | 77.53M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.59M |
| Total liabilities | 5.59M |
| Shareholder's equity | 71.94M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -59.98M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -59.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -74.22% |
| Return on Assets | -68.87% |
| Return on Invested Capital | -74.22% |
| Cash Return on Invested Capital | -83.38% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.20 |
| Daily high | 1.20 |
| Daily low | 1.14 |
| Daily Volume | 215K |
| All-time high | 156.13 |
| 1y analyst estimate | 3.10 |
| Beta | 1.75 |
| EPS (TTM) | -0.44 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KAN.ST | S&P500 | |
| Current price drop from All-time high | -99.23% | -12.89% |
| Highest price drop | -99.46% | -56.47% |
| Date of highest drop | 13 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -74.61% | -11.07% |
| Avg time to new high | 353 days | 12 days |
| Max time to new high | 1536 days | 1805 days |
COMPANY DETAILS
Marketcap
145.18M
Marketcap category
Small-cap
Description
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets react to higher-than-expected U.S. tariffs, major indices like the STOXX Europe 600 have experienced their steepest declines in five years, highlighting the growing uncertainty in ...
April 10, 2025